Tradestie Institutional Equity Comparison Engine

DYN vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DYN Overall Edge

DYN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dyne Therapeutics, Inc. Common Stock (DYN) driven by superior Valuation, Growth & Margin while ZBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DYN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, DYN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner DYN
DYN N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner DYN
Op Margin 0.0% vs -2747.5% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ZBIO
1Y -11.3% vs -21.7% ยท 52W Pos 20% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (25th %ile IV) vs CONSOLIDATION (13th %ile IV)
DYN NASDAQ
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$16.70
-2.68% 1D
Market Cap $3.2B
1M Return +17.19%
1Y Return -11.31%
Forward P/E N/M
Unified AI Score
47.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 71.0 Mom 60.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DYN -11.31% ZBIO -21.68% Spread: +10.37 pp (DYN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DYN TTM Op. Margin: 0.0% ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs ZBIO. Trailing 12-month operating profitability (DYN 0.0% vs ZBIO -2747.5%) and valuation multiples (DYN N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DYN (5) vs ZBIO (2)
Institutional Metric DYN ZBIO Criterion Row Winner
Market Capitalization Scale $3.2B $1.9B Larger Scale DYN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth DYN
Operating Margin (TTM) Profitability 0.0% -2747.5% Higher Margin DYN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -74.6% -265.1% Higher ROE DYN
52-Week Range Position Momentum 20% ($14โ€“$27) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.71ฮฒ ยท 58% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk DYN
Unified Institutional Score Composite Signal 47.5 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DYN vs ZBIO Buy Guide
DYN BREAKDOWN
68d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live DYN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DYN nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.